JAZZ News and Press, Jazz Pharmaceuticals plc From 08/10/22

In medicine, there is a term called “clinical inertia,” or the case of what someone doesn’t know — or what they ignore — could kill them. Simply put, it means failing to start or intensify a therapy when appropriate, which leads to advanced or chronic disea...

Commercial-stage biopharma Axsome Therapeutics ( NASDAQ: AXSM ) fell ~8% in the pre-market even after the company exceeded Street forecasts with its Q2 2022 financials on Tuesday as the investors focus on the regulatory path for the company’s depression candidate AXS-...

Jazz Pharmaceuticals plc (JAZZ) Q2 2022 Earnings Conference Call August 03, 2022 04:30 PM ET Company Participants Andrea Flynn - Vice President & Head-Investor Relations Bruce Cozadd - Chairman & Chief Executive Officer Dan Swisher - President Rob Ian...

Jazz Pharmaceuticals press release ( NASDAQ: JAZZ ): Q2 Non-GAAP EPS of $4.30 beats by $0.11 . Revenue of $932.88M (+24.1% Y/Y) beats by $30.37M . 2022 total revenue guidance affirmed at $3.5B to $3.7B vs. consensus of $3.6B. "We have achieved our net lever...

Jazz Pharmaceuticals Announces Second Quarter 2022 Financial Results and Affirms 2022 Financial Guidance PR Newswire DUBLIN , Aug. 3, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the second quarter of ...

Axsome Therapeutics encountered some regulatory setbacks relating to its lead medicine AXS05 for major depressive disorder. Axsome recently posted more positive data on AXS05 for such depression. More importantly, the firm indicated its upcoming labeling discussion for AXS05 with the ...

Jazz Pharmaceuticals to Report 2022 Second Quarter Financial Results on August 3, 2022 PR Newswire DUBLIN , July 20, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2022 second quarter financial results...

It's been a sad year for most investors, at least so far. With the S&P 500 in bear market territory (a drop of 20% or more from its most recent highs) and persistent geopolitical and economic problems, it's not clear that the end of these troubles is in sight. But some equities are ...

Cantor Fitgerald raised its price target on commercial-stage biopharma Axsome Therapeutics ( NASDAQ: AXSM ) by as much as ~36% noting that the company’s management provided a much clearer view on sleep disorder therapy Sunosi at an investor event on Tuesday. In Ma...

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced top-line results from the Phase 3 RELEASE MSS1 trial ( NCT04657666 ) evaluating nabiximols oromucosal spray (JZP378, or Sativex , ex-U.S.) on clinical measures of spasticity in individuals with multiple sclerosis (MS). ...